164 related articles for article (PubMed ID: 15070711)
21. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
[TBL] [Abstract][Full Text] [Related]
22. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.
Sandoval C; Pine SR; Guo Q; Sastry S; Stewart J; Kronn D; Jayabose S
Pediatr Blood Cancer; 2005 Jan; 44(1):85-91. PubMed ID: 15390279
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down's syndrome.
Hirose Y; Kudo K; Kiyoi H; Hayashi Y; Naoe T; Kojima S
Leukemia; 2003 Nov; 17(11):2250-2. PubMed ID: 12931214
[No Abstract] [Full Text] [Related]
24. Natural history of GATA1 mutations in Down syndrome.
Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
[TBL] [Abstract][Full Text] [Related]
25. The proto-oncogene ERG in megakaryoblastic leukemias.
Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
[TBL] [Abstract][Full Text] [Related]
26. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
Terui K; Toki T; Taga T; Iwamoto S; Miyamura T; Hasegawa D; Moritake H; Hama A; Nakashima K; Kanezaki R; Kudo K; Saito AM; Horibe K; Adachi S; Tomizawa D; Ito E
Genes Chromosomes Cancer; 2020 Mar; 59(3):160-167. PubMed ID: 31606922
[TBL] [Abstract][Full Text] [Related]
27. Transient leukaemia in newborn infants with trisomy 21.
Kwong YL
Br J Haematol; 2003 Aug; 122(4):686-7. PubMed ID: 12899726
[No Abstract] [Full Text] [Related]
28. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Druschel CM; Sandoval C
Blood; 2007 Sep; 110(6):2128-31. PubMed ID: 17576817
[TBL] [Abstract][Full Text] [Related]
29. GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications.
Hitzler J; Zipursky A
Leuk Res; 2005 Nov; 29(11):1239-40. PubMed ID: 15925405
[No Abstract] [Full Text] [Related]
30. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome.
Ito E; Kasai M; Hayashi Y; Toki T; Arai K; Yokoyama S; Kato K; Tachibana N; Yamamoto M; Yokoyama M
Br J Haematol; 1995 Jul; 90(3):607-14. PubMed ID: 7647001
[TBL] [Abstract][Full Text] [Related]
31. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.
Xu G; Nagano M; Kanezaki R; Toki T; Hayashi Y; Taketani T; Taki T; Mitui T; Koike K; Kato K; Imaizumi M; Sekine I; Ikeda Y; Hanada R; Sako M; Kudo K; Kojima S; Ohneda O; Yamamoto M; Ito E
Blood; 2003 Oct; 102(8):2960-8. PubMed ID: 12816863
[TBL] [Abstract][Full Text] [Related]
32. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.
Groet J; McElwaine S; Spinelli M; Rinaldi A; Burtscher I; Mulligan C; Mensah A; Cavani S; Dagna-Bricarelli F; Basso G; Cotter FE; Nizetic D
Lancet; 2003 May; 361(9369):1617-20. PubMed ID: 12747884
[TBL] [Abstract][Full Text] [Related]
33. Down syndrome and GATA1-related transient leukemia.
Sandoval C; Pine SR
J Pediatr; 2007 Mar; 150(3):e34. PubMed ID: 17307526
[No Abstract] [Full Text] [Related]
34. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults.
Kiyoi H; Yamaji S; Kojima S; Naoe T
Leukemia; 2007 Mar; 21(3):574-6. PubMed ID: 17252020
[No Abstract] [Full Text] [Related]
35. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
[TBL] [Abstract][Full Text] [Related]
36. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation.
Magalhães IQ; Splendore A; Emerenciano M; Córdoba MS; Córdoba JC; Allemand PA; Ferrari I; Pombo-de-Oliveira MS
J Pediatr Hematol Oncol; 2005 Jan; 27(1):50-2. PubMed ID: 15654280
[TBL] [Abstract][Full Text] [Related]
37. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.
Gurbuxani S; Vyas P; Crispino JD
Blood; 2004 Jan; 103(2):399-406. PubMed ID: 14512321
[TBL] [Abstract][Full Text] [Related]
38. GATA1 in normal and malignant hematopoiesis.
Crispino JD
Semin Cell Dev Biol; 2005 Feb; 16(1):137-47. PubMed ID: 15659348
[TBL] [Abstract][Full Text] [Related]
39. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
40. Mutation characterization in the GATA-1 gene in patients with Down's Syndrome diagnosed with transient abnormal myelopoiesis or acute megakaryoblastic leukemia.
Mansini AP; Rubio PL; Rossi JG; Gallego MS; Medina A; Zubizarreta PA; Felice MS; Alonso CN
Arch Argent Pediatr; 2013 Dec; 111(6):532-6. PubMed ID: 24196768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
